Αποτελέσματα Αναζήτησης
3 Δεκ 2020 · Among 984 cases of breast cancer during pregnancy, an increased risk of stillbirth assessed as small gestational age, preterm delivery, and neonatal mortality largely caused by iatrogenic preterm birth was reported; thus, careful monitoring on fetal growth and decisions on the timing of the delivery, aiming to a full term delivery, are critical ...
- Figure 2
The diagnosis of cancer during pregnancy represents a...
- Table 1
Main results of the studies assessing the use of...
- Open in a Separate Window
The diagnosis of cancer during pregnancy represents a...
- Figure 2
10 Αυγ 2023 · In the shared decision-making process, we need to integrate multifaceted information, including cancer stage and relapse risk, weeks of pregnancy and the patient’s desire to bear children, and use it to examine viable treatment options (V).
8 Οκτ 2014 · Based on these data, TC is considered a standard regimen for adjuvant therapy for node-negative or low-risk node-positive breast cancer. 25 For high-risk breast cancer, good evidence suggests that four cycles of TC is inferior to sequential AC-T (even when concurrent anthracycline is added to TC). 26, 27 Although AC-T has superior breast cancer ...
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
26 Απρ 2016 · Less cardiotoxicity is seen with TCH (docetaxel, carboplatin, and trastuzumab) than with AC→TH (doxorubicin and cyclophosphamide→docetaxel and trastuzumab), and TCH is recommended for patients at higher risk for cardiotoxicity.*
10 Σεπ 2020 · In the rare case of a cancer diagnosis during pregnancy, our imperative as oncologists is to guide patients toward informed treatment decisions that appropriately balance the relative risks to both the mother and the fetus.
Here we report outcomes for patients with localized HER2+ breast cancer treated with pertuzumab-containing neoadjuvant regimens and AC-TH. Methods:
